Meet us at CPHI Milan 2026, Booth No. 10H33, Oct 6-8, Fiera Milano, Italy Schedule a Meeting
From route design to cGMP manufacturing — built for scale, control, and continuity.
Discuss Your MoleculeDeveloping small molecule APIs involves more than route execution. Programs often face challenges in process efficiency, impurity control, scalability, analytical readiness, and regulatory alignment especially as they move toward clinical and commercial manufacturing.
Neuland’s small molecule CDMO services are designed to help pharma and biotech companies progress challenging complex APIs across the development lifecycle, from early-phase process development to late-stage manufacturing. We combine process chemistry, scale-up expertise, analytical development, manufacturing execution, and regulatory CMC support to create a more reliable path from lab to plant.
Our small molecule capabilities are designed to support programs across each stage of development from early route design for new NCEs to scale-up, commercial manufacturing, and regulatory readiness. Each capability is built to address specific technical and operational challenges while ensuring continuity as your program progresses.
Design scalable, phase-appropriate processes for complex small molecule APIs.
Neuland supported a small molecule API program facing low yields, process inefficiencies, and scale-up challenges in early development. By applying a phase-appropriate process optimisation strategy, the team improved yield, reduced cost, and enabled a smoother transition to larger-scale production.
Our approach is built to translate complex chemistry into reliable manufacturing with stronger process understanding, smoother scale-up, and greater confidence in execution.
Extensive experience supporting new chemical entities across development stages.
Partner with Neuland to navigate complex chemistry, scale-up challenges, and manufacturing execution from early development through commercial API supply.
Answers to key questions regarding small molecule API CDMO services, scale-up, analytical support, and regulatory CMC.
Still Have Questions? Contact UsA small molecule CDMO supports the development, scale-up, and manufacturing of small molecule APIs. This includes process development, analytical support, cGMP manufacturing, and regulatory CMC documentation, helping pharma and biotech companies advance programs from early development through commercial supply.
Yes. Neuland supports both small molecule API development and manufacturing under a single partner model. This enables a seamless transition from early-phase process development to clinical and commercial API production, reducing tech transfer risks and ensuring continuity across development stages.
Neuland supports a wide range of small molecule APIs, including complex and early-stage molecules. This includes new chemical entities (NCEs), multi-step synthetic molecules, and APIs requiring strong impurity control and scalable process development.
Scale-up is managed through structured process development and close alignment between development and manufacturing teams. This involves identifying critical process parameters early and designing scalable, reproducible processes to ensure a smoother transition from lab-scale development to commercial production.
Yes. Neuland provides analytical development and validation across all stages of small molecule API programs. This includes method development, validation, impurity profiling, and stability support, ensuring reliable data and consistent product quality.
Neuland provides Regulatory CMC support to help advance small molecule APIs through global filings. This includes preparation of CMC documentation, support for regulatory submissions, and alignment of development, analytical, and manufacturing data with regulatory expectations.
Yes. Neuland supports both the development and manufacturing of intermediates and key starting materials (KSMs). This helps strengthen upstream supply and improve overall program reliability, especially for complex small molecule APIs.
A company should engage a small molecule CDMO as early as route selection or process development. Early engagement helps establish scalable processes, identify potential risks, and align development with manufacturing and regulatory requirements, while support can also be provided at later clinical or commercial stages.
Reliable cGMP manufacturing from clinical supply to commercial production.
Robust analytical methods to support product quality and regulatory readiness.
Structured documentation and regulatory support across development stages.
